Lymphoma Clinical Trials

Showing 1241-1260 of 1,633 trials

Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02708732

This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey. The project is designed to describe the impact of DLBCL remission on health utility and quality of life. Data collection will occur over a 4-month period.

Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche91 participantsStarted May 2016

Marlow, United Kingdom

COMPLETEDPhase 1

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT01471210

The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

Bristol-Myers Squibb124 participantsStarted Feb 2012

Los Angeles, California, United States • Stanford, California, United States • Chicago, Illinois, United States +21 more locations

Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Related Searches

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Lenalidomide After Allo Transplant

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Primary Rituximab and Maintenance

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Treatment of Aggressive Localized Lymphoma

Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment